Anlon Healthcare IPO
Bookbuilding IPO | ₹121.00 Cr | Listing at BSE, NSE
IPO Open
Tue, Aug 26, 2025
IPO Close
Fri, Aug 29, 2025
Price Band
₹86.00 to ₹91.00
Market Cap (Pre-IPO)
₹483.68 Cr
IPO Details
| IPO Date | Aug 26, 2025 to Aug 29, 2025 |
| Listing Date | Tentative: Sep 03, 2025 |
| Face Value | ₹10.00 per share |
| Price Band | ₹86.00 to ₹91.00 |
| Lot Size | 164 Shares (Minimum: ₹14,924.00) |
| Sale Type | Offer For Sale + Fresh Issue |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Issue Size | ₹121.00 Crores |
| Total Shares Offered | 13,300,000 shares |
| Offer For Sale | 13,300,000 shares |
Subscription Data
| Category | Times Subscribed |
|---|---|
| QIB | 1.07x |
| NII | 10.61x |
| RII | 47.26x |
| Total | 7.12x |
Anlon Healthcare IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | 99,75,000 (75.00%) |
| Retail Shares Offered | 13,30,000 (10.00%) |
| NII Shares Offered | 19,95,000 (15.00%) |
Anlon Healthcare IPO Lot Size
Investors can bid for a minimum of 164 shares and in multiples thereof
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹194,012 |
| S-HNI (Min) | 14 | 2,296 | ₹208,936 |
| S-HNI (Max) | 67 | 10,988 | ₹999,908 |
| B-HNI (Min) | 68 | 11,152 | ₹1,014,832 |
Anlon Healthcare Financial Information (Restated Consolidated)
Anlon Healthcare Ltd.'s revenue increased by 81% and profit after tax (PAT) rose by 112% between the financial year ending with March 31, 2025 and March 31, 2024
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| NET Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
Amount in ₹ Cr
Key Performance Indicators
As of Monday, March 31, 2025| KPI | Values |
|---|---|
| ROE (Return on Equity) | 40.45% |
| ROCE (Return on Capital Employed) | 21.93% |
| Debt/Equity | 0.73 |
| RoNW (Return on Net Worth) | 25.51% |
| PAT Margin (Profit After Tax Margin) | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS Rs | 5.15 | 3.86 |
| P/E (x) | 17.67 | 23.57 |
| Promoter Holding | 70.26% | 52.68% |
Company Promoters
- Punitkumar R. rasadia
- Meet Atulkumar Vachhani and Mamata punitkumar Rasadia are the promoters of the company.
Company Overview
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).
The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).
The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.
In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.
The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.
The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.
The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage.
Products:
- Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
- Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.
Company Strengths
- Strong product portfolio and scalable business.
- Strong Promoters and Experienced Management Team.
- High entry and exit barriers due to long customer approval cycles and strict product standards.
- In-house Testing, Quality Control and Quality Assurance for quality control.
- Focus on Quality, Environment, Health and Safety.
Use of Proceeds
| 1) | Funding capital expenditure requirements for Proposed Expansion | 30.72 |
| 2) | Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company | 5.00 |
| 3) | Funding the working capital requirements of the Company | 43.15 |
| 4) | General corporate purposes | 270.30 |
Objectives
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Anlon Healthcare IPO Peer Comparison
Anlon Healthcare peer comparison with similar listed entities. (As on March 31, 2025)| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Anlon Healthcare | 6.38 | 6.38 | 20.18 | 0.00 | 25.51 | 0.00 | Standalone |
| Kronox Lab Sciences | 6.91 | 6.91 | 24.28 | 26.18 | 28.26 | 7.50 | Standalone |
| Acutaas Chemicals | 19.81 | 19.81 | 161.24 | 58.47 | 12.15 | 7.19 | Standalone |
| Supriya Lifeciences | 23.35 | 23.35 | 123.85 | 29.27 | 18.86 | 5.55 | Standalone |
Quick Info
| Sector | Pharmaceuticals (Pharma) |
| Exchange | BSE, NSE |
| Market Cap (Pre-IPO) | ₹483.68 Cr |
| GMP | 0.00 |
Important Dates
| IPO Open | Aug 26, 2025 |
| IPO Close | Aug 29, 2025 |
| Allotment Date | Sep 01, 2025 |
| Credit to Demat | Sep 02, 2025 |
| Listing Date | Tentative: Sep 03, 2025 |
Lead Manager(s)
Interactive Financial Services Ltd.
Registrar
Kfin Technologies Ltd.
04067162222, 04079611000
Description
- Anlon Healthcare IPO is a book build issue of ₹121.03 crores. The issue is entirely a fresh issue of 1.33 crore shares of ₹121.03 crore.
- Anlon Healthcare IPO bidding started from Aug 26, 2025 and ended on Aug 29, 2025. The allotment for Anlon Healthcare IPO was finalized on Sep 1, 2025. Anlon Healthcare IPO will list on BSE, NSE with a tentative listing date fixed as Sep 3, 2025.
- Anlon Healthcare IPO price band is set at ₹91.00 per share . The lot size for an application is 164. The minimum amount of investment required by an retail is ₹14,924 (164 shares) (based on upper price). The lot size investment for sNII is 14 lots (2,296 shares), amounting to ₹2,08,936, and for bNII, it is 68 lots (11,152 shares), amounting to ₹10,14,832